uniQure (NASDAQ:QURE) Earns Buy Rating from Guggenheim
uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports. They currently have a $28.00 price target on the biotechnology company’s stock. Guggenheim’s price objective suggests a potential upside of 118.58% from the stock’s current price. A number of […]
